{"id":"https://openalex.org/W4394674174","doi":"https://doi.org/10.1182/bloodadvances.2023012142","title":"An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL","display_name":"An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL","publication_year":2024,"publication_date":"2024-04-10","ids":{"openalex":"https://openalex.org/W4394674174","doi":"https://doi.org/10.1182/bloodadvances.2023012142","pmid":"https://pubmed.ncbi.nlm.nih.gov/38598745","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11176945"},"language":"en","primary_location":{"id":"doi:10.1182/bloodadvances.2023012142","doi":"https://doi.org/10.1182/bloodadvances.2023012142","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2023012142","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023012142/2221734/bloodadvances.2023012142.pdf","source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023012142/2221734/bloodadvances.2023012142.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069318162","display_name":"Adam S. Kittai","orcid":"https://orcid.org/0000-0002-4891-6144","observed_orcids":["https://orcid.org/0000-0002-4891-6144"]},"institutions":[{"id":"https://openalex.org/I2799885155","display_name":"The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","ror":"https://ror.org/028t46f04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Adam S. Kittai","raw_affiliation_strings":["1Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH","institution_ids":["https://openalex.org/I2799885155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026842309","display_name":"John Nathan Allan","orcid":"https://orcid.org/0000-0002-2088-0899","observed_orcids":["https://orcid.org/0000-0002-2088-0899"]},"institutions":[{"id":"https://openalex.org/I1340179700","display_name":"NewYork\u2013Presbyterian Hospital","ror":"https://ror.org/03gzbrs57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1340179700"]},{"id":"https://openalex.org/I205783295","display_name":"Cornell University","ror":"https://ror.org/05bnh6r87","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295"]},{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John N. Allan","raw_affiliation_strings":["2Weill Cornell Medicine, New York, NY","Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, United States"],"raw_orcid":"https://orcid.org/0000-0002-2088-0899","affiliations":[{"raw_affiliation_string":"2Weill Cornell Medicine, New York, NY","institution_ids":["https://openalex.org/I4387153466"]},{"raw_affiliation_string":"Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, United States","institution_ids":["https://openalex.org/I1340179700","https://openalex.org/I205783295"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111170545","display_name":"Dan James","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dan James","raw_affiliation_strings":["3Polaris Biostatistics Ltd, Edinburgh, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Polaris Biostatistics Ltd, Edinburgh, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108985770","display_name":"Helen Bridge","orcid":"https://orcid.org/0000-0001-5499-2496","observed_orcids":["https://orcid.org/0000-0001-5499-2496"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Helen Bridge","raw_affiliation_strings":["4AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103826171","display_name":"Miguel Miranda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Miguel Miranda","raw_affiliation_strings":["4AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104180192","display_name":"Alan SM Yong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alan S. M. Yong","raw_affiliation_strings":["5AstraZeneca, Gaithersburg, MD","AstraZeneca, Gaithersburg, Maryland, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5AstraZeneca, Gaithersburg, MD","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"AstraZeneca, Gaithersburg, Maryland, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093395707","display_name":"Fady Fam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Fady Fam","raw_affiliation_strings":["4AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056676664","display_name":"Jack Roos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jack Roos","raw_affiliation_strings":["5AstraZeneca, Gaithersburg, MD","AstraZeneca, Gaithersburg, Maryland, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5AstraZeneca, Gaithersburg, MD","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"AstraZeneca, Gaithersburg, Maryland, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Vikram Shetty","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vikram Shetty","raw_affiliation_strings":["5AstraZeneca, Gaithersburg, MD","AstraZeneca, Gaithersburg, Maryland, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5AstraZeneca, Gaithersburg, MD","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"AstraZeneca, Gaithersburg, Maryland, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010673295","display_name":"Alan Pierre Zausner Skarbnik","orcid":"https://orcid.org/0000-0002-1276-7546","observed_orcids":["https://orcid.org/0000-0002-1276-7546"]},"institutions":[{"id":"https://openalex.org/I2802152183","display_name":"Novant Health","ror":"https://ror.org/04nv2wh79","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802152183"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alan Skarbnik","raw_affiliation_strings":["6Novant Health Cancer Institute, Lymphoma and CLL Program, Charlotte, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Novant Health Cancer Institute, Lymphoma and CLL Program, Charlotte, NC","institution_ids":["https://openalex.org/I2802152183"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5069318162"],"corresponding_institution_ids":["https://openalex.org/I2799885155"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":{"value":3000,"currency":"USD","value_usd":3000},"fwci":5.5713,"has_fulltext":true,"cited_by_count":21,"citation_normalized_percentile":{"value":0.97044728,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"8","issue":"11","first_page":"2861","last_page":"2869"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acalabrutinib","display_name":"acalabrutinib","score":0.859000027179718},{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/zanubrutinib","display_name":"zanubrutinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9850000143051147},{"id":"https://openalex.org/keywords/small-lymphocytic-lymphoma","display_name":"small lymphocytic lymphoma","score":0.9919999837875366},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.8939999938011169},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8140000104904175},{"id":"https://openalex.org/keywords/indirect-comparison","display_name":"indirect comparison","score":0.6940000057220459},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.5210000276565552},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":1.0},{"id":"https://openalex.org/keywords/joint-pain","display_name":"joint pain","score":0.9940000176429749},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.871999979019165}],"concepts":[{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.6869591474533081},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.656516969203949},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6111055016517639},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.5885831713676453},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5036012530326843},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4802956283092499},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.47320741415023804},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.46983784437179565},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.4250728487968445},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.23096972703933716},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.22803577780723572},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.11606448888778687}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1182/bloodadvances.2023012142","doi":"https://doi.org/10.1182/bloodadvances.2023012142","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2023012142","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023012142/2221734/bloodadvances.2023012142.pdf","source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11176945","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11176945","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11176945/pdf/main.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Adv","raw_type":"Text"},{"id":"pmid:38598745","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38598745","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood advances","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1182/bloodadvances.2023012142","doi":"https://doi.org/10.1182/bloodadvances.2023012142","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2023012142","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023012142/2221734/bloodadvances.2023012142.pdf","source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G302703441","display_name":null,"funder_award_id":"GPP 2022","funder_id":"https://openalex.org/F4320308573","funder_display_name":"Gilead Sciences"},{"id":"https://openalex.org/G6349302465","display_name":null,"funder_award_id":"GPP 2022","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G7275711376","display_name":null,"funder_award_id":"GPP 2022","funder_id":"https://openalex.org/F4320307770","funder_display_name":"AstraZeneca"},{"id":"https://openalex.org/G7464895513","display_name":null,"funder_award_id":"GPP 2022","funder_id":"https://openalex.org/F4320312570","funder_display_name":"Jazz Pharmaceuticals"},{"id":"https://openalex.org/G9000873194","display_name":"Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia","funder_award_id":"R01CA266298","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320306239","display_name":"Conquer Cancer Foundation","ror":"https://ror.org/027327e78"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320308982","display_name":"American Society of Clinical Oncology","ror":"https://ror.org/04fy6j421"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320312570","display_name":"Jazz Pharmaceuticals","ror":"https://ror.org/055mhsv54"},{"id":"https://openalex.org/F4320313971","display_name":"TG Therapeutics","ror":"https://ror.org/00pwykz63"},{"id":"https://openalex.org/F4320316491","display_name":"MEI Pharma","ror":"https://ror.org/02bgfrc80"},{"id":"https://openalex.org/F4320317235","display_name":"BeiGene","ror":"https://ror.org/012v2c923"},{"id":"https://openalex.org/F4320319131","display_name":"Ascentage Pharma","ror":"https://ror.org/053nqfd77"},{"id":"https://openalex.org/F4320319515","display_name":"Seagen","ror":null},{"id":"https://openalex.org/F4320328062","display_name":"MorphoSys","ror":"https://ror.org/00ew7rg06"},{"id":"https://openalex.org/F4320328455","display_name":"Ipsen","ror":"https://ror.org/00d801g55"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320333648","display_name":"Pharmacyclics","ror":"https://ror.org/03hm8w204"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4394674174.pdf","grobid_xml":"https://content.openalex.org/works/W4394674174.grobid-xml"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W1931149717","https://openalex.org/W1982967337","https://openalex.org/W2120319857","https://openalex.org/W2318933236","https://openalex.org/W2558697804","https://openalex.org/W2621070985","https://openalex.org/W2750906538","https://openalex.org/W2788803761","https://openalex.org/W2902484351","https://openalex.org/W2922286357","https://openalex.org/W2950162648","https://openalex.org/W2976280418","https://openalex.org/W2980937306","https://openalex.org/W3016538158","https://openalex.org/W3082899459","https://openalex.org/W3151974300","https://openalex.org/W3157209850","https://openalex.org/W3169509540","https://openalex.org/W3181526846","https://openalex.org/W3185756680","https://openalex.org/W3191871611","https://openalex.org/W3199413822","https://openalex.org/W4205825534","https://openalex.org/W4284883545","https://openalex.org/W4307773195","https://openalex.org/W4311293040","https://openalex.org/W4361004154","https://openalex.org/W4387440695"],"related_works":["https://openalex.org/W4389229579","https://openalex.org/W7164382966","https://openalex.org/W7125693677","https://openalex.org/W3011180414","https://openalex.org/W2992300027","https://openalex.org/W3157209850","https://openalex.org/W4417012349","https://openalex.org/W2987552010","https://openalex.org/W3016538158","https://openalex.org/W2953070007"],"abstract_inverted_index":{"ABSTRACT:":[0],"The":[1],"efficacy":[2],"and":[3,9,106,152,182,207],"safety":[4,166],"of":[5,75,86,124,145,180,195],"acalabrutinib":[6,10,44,94,109,138,171,187],"plus":[7,39,95,139,172],"obinutuzumab":[8,96,140,173],"monotherapy":[11,110,119,188],"vs":[12,116,128,159],"zanubrutinib":[13,129],"in":[14,80,165],"patients":[15,63],"with":[16,64,93,108,177,192],"treatment-naive":[17],"chronic":[18],"lymphocytic":[19,21],"leukemia/small":[20],"lymphoma":[22],"without":[23],"del(17p)":[24,65],"were":[25,49,73,167,201],"compared":[26],"using":[27,70],"an":[28,81],"unanchored":[29],"matching-adjusted":[30],"indirect":[31],"comparison.":[32],"Individual":[33],"patient-level":[34],"data":[35,56],"from":[36,57],"ELEVATE-TN":[37],"(acalabrutinib":[38],"obinutuzumab,":[40],"n":[41,46,67],"=":[42,47,68],"162;":[43],"monotherapy,":[45],"163)":[48],"weighted":[50],"to":[51],"match":[52],"published":[53],"aggregate":[54],"baseline":[55],"SEQUOIA":[58],"cohort":[59],"1,":[60],"which":[61],"excluded":[62],"(zanubrutinib,":[66],"241),":[69],"variables":[71],"that":[72],"prognostic/predictive":[74],"investigator-assessed":[76],"progression-free":[77],"survival":[78],"(INV-PFS)":[79],"exploratory":[82],"Cox":[83],"regression":[84],"analysis":[85],"ELEVATE-TN.":[87],"After":[88],"matching,":[89],"INV-PFS":[90,176,191],"was":[91],"longer":[92,175],"(hazard":[97],"ratio":[98,131],"[HR],":[99],"0.41;":[100],"95%":[101,113,134,149,156],"confidence":[102],"interval":[103],"[CI],":[104],"0.23-0.74)":[105],"comparable":[107],"(HR,":[111],"0.91;":[112],"CI,":[114,135,150,157],"0.53-1.56)":[115],"zanubrutinib.":[117,160],"Acalabrutinib":[118],"had":[120,141,174,189],"significantly":[121,142],"lower":[122,193],"odds":[123,144,179,194],"any":[125,196],"grade":[126,197],"hypertension":[127],"(odds":[130],"[OR],":[132],"0.44;":[133],"0.20-0.99),":[136],"whereas":[137,186],"higher":[143],"neutropenia":[146,181],"(OR,":[147,154],"2.19;":[148],"1.33-3.60)":[151],"arthralgia":[153,183],"2.33;":[155],"1.37-3.96)":[158],"No":[161],"other":[162],"significant":[163],"differences":[164],"observed.":[168],"In":[169],"summary,":[170],"increased":[178],"than":[184],"zanubrutinib,":[185],"similar":[190],"hypertension.":[198],"These":[199],"trials":[200],"registered":[202],"at":[203],"www.ClinicalTrials.gov":[204],"as":[205],"#NCT02475681":[206],"#NCT03336333.":[208]},"counts_by_year":[{"year":2026,"cited_by_count":11},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2024-04-11T00:00:00"}